Citations

Clear

626 citation(s) found for "Mehta, SH".

Increased Length of Stay Associated With Antibiotic Use in Older Adults With Advanced Cancer Transitioned to Comfort Measures
Datta, Rupak , Zhu, Mojun , Allore, Heather , Quagliarello, Vincent, Juthani‐Mehta, Manisha, Han, Ling

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | June 11, 2019 | Volume: 37 | Issue: 1 | Pages: 27-33

10.1177/1049909119855617 | PMID 31185722 Get It

Background: Antibiotic use may increase hospital length of stay (LOS) among older patients with advanced cancer who are transitioned to comfort measures. Methods: We studied a cohort of patients with advanced cancer aged ≥65 years who were transitioned to comfort measures during admission from July 1, 2014, through November 30, 2016. We evaluated the association between antibiotic exposure and LOS using a Poisson regression model adjusted for age, gender, cancer type, comorbidities, infection, and intensive care unit admission. Results: Among 461 patients with advanced cancer, median age was 74 years (range: 65-99), 49.0% (n = 226) were female, and 20.6% (n = 95) had liquid tumors. Overall, 82.9% (n = 382) received ≥1 antibiotic and 64.6% (n = 298) had ≥1 infection diagnosis during hospitalization. Infection diagnoses commonly included sepsis (35%, n = 161/461), pneumonia (25%, n = 117/461), and urinary tract infection (14%, n = 66/461). Among those receiving antibiotics, the most common choices included vancomycin (79%, n = 300/382), cephalosporins (63%, n = 241/382), and penicillins (45%, n = 172/382). In a multivariable Poisson regression model, LOS was 34% longer (count ratio = 1.34, [95% confidence interval: 1.20-1.51]) among those exposed versus unexposed to antibiotics. Conclusions: Antibiotic use among patients with advanced cancer who are transitioned to comfort measures is associated with longer LOS. These data illustrate the importance of tradeoffs associated with antibiotic use, such as unintended increased LOS, when striving for goal-concordant care near the end of life.
Barriers to accrual and enrollment in brain tumor trials
Lee, Eudocia Q. , Chukwueke, Ugonma , Hervey‐Jumper, Shawn L. , Leone, José Pablo , Chang, Susan M. , Arons, David, Oliver, Kathy , Verble, Kay, Musella, Al , Willmarth, Nicole E. , Doherty, Lisa, Gaffey, Sarah, Halkin, Thomas, Friday, Bret Edward Buckley, Fouladi, Maryam , Macdonald, David R., Peñas-Prado, Marta , Vogelbaum, Michael A. , Sahebjam, Solmaz , Sandak, David, Bent, Martin J. van den , Weller, Michael , Reardon, David A. , Wen, Patrick Y. , Galanis, Evanthia , Weller, Michael , van den Bent, Martin J , Groot, John de , Armstrong, Terri S. , Chang, Susan Marina , Alexander, Brian M. , Bates, Amanda, Lin, Nancy U. , Mehta, Minesh P. , Wen, Patrick Yung

Mayo Clinic

Neuro-Oncology | June 7, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/neuonc/noz104 | PMID 31175826 Get It

Abstract Many factors contribute to the poor survival of malignant brain tumor patients, some of which are not easily remedied. However, one contributor to the lack of progress that may be modifiable is poor clinical trial accrual. Surveys of brain tumor patients and neuro-oncology providers suggest that clinicians do a poor job of discussing clinical trials with patients and referring patients for clinical trials. Yet, data from the Cancer Action Network of the American Cancer Society suggest that most eligible oncology patients asked to enroll on a clinical trial will agree to do so. To this end, the Society for Neuro-Oncology (SNO) in collaboration with the Response Assessment in Neuro-Oncology (RANO) Working Group, patient advocacy groups, clinical trial cooperative groups, including the Adult Brain Tumor Consortium (ABTC), and other partners are working together with the intent to double clinical trial accrual over the next 5 years. Here we describe the factors contributing to poor clinical trial accrual in neuro-oncology and offer possible solutions.
A phase II study of TAS-102 in combination with ramucirumab in advanced, refractory gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Shah, Neal, Carballido, Estrella M., Imanirad, Iman , Kim, Dae Won , Mehta, Rutika Jitesh , Kim, Richard D. , Shah, Neal, Kim, Youngchul

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: TPS4149-TPS4149

10.1200/jco.2019.37.15_suppl.tps4149 Get It

TPS4149 Background: Patients with advanced gastric cancer experience a 5 year survival rate <10% even with multimodality therapy representing a clear unmet need for improved treatment. In advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma, ramucirumab (a monoclonal antibody against VEGFR2) has demonstrated clinical activity and has been approved as second line therapy in combination with paclitaxel with a response rate of 28% and absolute overall survival benefit of 8 weeks when compared to placebo. However, there are many patients that cannot tolerate paclitaxel due to prior exposure to oxaliplatin causing neuropathy. Therefore, novel combinations with ramucirumab, is highly desirable. TAS-102 is an oral cytotoxic agent with two active components; trifluridine (TFD) which inhibits tumor cell growth by being incorporated into DNA during DNA synthesis and tipiracil (TPI) which inhibits the metabolism of TFD, thereby prolonging its ability to exert effect. TPI also inhibits platelet derived endothelial cell growth factor which plays a key role with VEGF in tumor angiogenesis. The combination of a cytotoxic agent with an antiangiogenic agent has demonstrated a significant anticancer activity in multiple cancers. In a recent Phase III study, TAS-102 significantly prolonged overall survival as compared to best supportive care in patients with GEJ and gastric cancers that had received at least 2 prior lines of treatment. We hypothesize that a combination of TAS-102 and ramucirumab might increase efficacy without causing unmanageable toxicity. Methods: This is a single institutional phase II single arm two-stage design trial using the combination of TAS-102 and ramucirumab in advanced, refractory gastric or GEJ adenocarcinoma. Eligible patients include those with histologically confirmed gastric or GEJ adenocarcinoma that have received at least 1 prior line of treatment with performance status 0 or 1 and preserved organ function. Ramucirumab will be administered 8mg/kg every 2 weeks and TAS-102 at doses of 35 mg/m2 twice daily. Each cycle length will be 28 days. The primary endpoint is 6 month OS and secondary endpoints are safety, objective response rate and PFS. Fifteen patients will be enrolled in the first stage. If ≥ 7 of the 15 are alive at 6 months, an additional 10 patients will be enrolled in the second phase. Enrollment is currently ongoing. Clinical trial information: NCT03686488.
Barriers to accrual and enrollment in brain tumor trials.
Lee, Eudocia Q. , Chukwueke, Ugonma , Hervey‐Jumper, Shawn L. , Groot, John Frederick De, Leone, José Pablo , Chang, Susan M. , Arons, David, Oliver, Kathy , Friday, Bret Edward Buckley, Penas‐Prado, Marta, Vogelbaum, Michael A. , Sahebjam, Solmaz , Bent, Martin J. van den , Reardon, David A. , Wen, Patrick Y. , van den Bent, Martin J , Armstrong, Terri S. , Chang, Susan Marina , Galanis, Evanthia , Lin, Nancy U. , Mehta, Minesh P. , Peñas-Prado, Marta , Weller, Michael , Wen, Patrick Yung

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: 2024-2024

10.1200/jco.2019.37.15_suppl.2024 Get It

2024 Background: A major impediment to improving neuro-oncology outcomes is poor clinical trial accrual. Methods: We convened a multi-stakeholder group including Society for Neuro-Oncology, Response Assessment in Neuro-Oncology, patient advocacy groups, clinical trial cooperative groups, and other partners to determine how we can improve trial accrual. Results: We describe selected factors contributing to poor trial accrual and possible solutions. Conclusions: We will implement strategies with the intent to double trial accrual over the next 5 years. [Table: see text]
NRG Oncology CC001: A phase III trial of hippocampal avoidance (HA) in addition to whole-brain radiotherapy (WBRT) plus memantine to preserve neurocognitive function (NCF) in patients with brain metastases (BM).
Gondi, Vinai , Deshmukh, Snehal, Brown, Paul D. , Tomé, Wolfgang A. , Bovi, Joseph , Khuntia, Deepak , Grosshans, David R. , Konski, André , Devisetty, Kiran , Shah, Sunjay, Usuki, Kenneth Y., Anderson, Bethany , Kachnic, Lisa A. , Wefel, Jeffrey S. , Armstrong, Terri S. , Bruner, Deborah Watkins , Robinson, Clifford G. , Roberge, David , Kundapur, Vijayananda , Mehta, Minesh P.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: 2009-2009

10.1200/jco.2019.37.15_suppl.2009 Get It

2009 Background: NRG CC001, a phase III trial of WBRT plus memantine (WBRT+M) with or without HA, sought to evaluate the neuro-protective effects of lowering the hippocampal radiation dose. Methods: Patients (pts) with BM were stratified by RPA class and prior radiosurgery/surgery and randomized to WBRT+M or HA-WBRT+M (30Gy/10 fractions). Standardized NCF tests were performed at baseline, 2, 4, 6, and 12 months (mos). The primary endpoint was NCF failure, defined as decline using the reliable change index on Hopkins Verbal Learning Test-Revised, Trail Making Test, or Controlled Oral Word Association. Cumulative incidence estimated NCF failure (death without NCF failure was competing risk); between-arms differences tested using Gray’s test. Deterioration at each collection time point was tested using a chi-square test. Patient-reported symptoms were assessed using the MD Anderson Symptom Inventory Brain Tumor module and analyzed using mixed effects models and t-tests. Results: From 7/2016 to 3/2018, 518 pts were randomized. Median follow-up was 7.9 mos. HA-WBRT+M was associated with lower NCF failure risk (adjusted hazard ratio (HR) = 0.74, p = 0.02) due to lower risk of deterioration in executive function at 4 mos (p = 0.01) and encoding (p = 0.049) and consolidation (p = 0.02) at 6 mos. Age≤61 predicted lower NCF failure risk (HR = 0.60, p = 0.0002); non-significant test for interaction indicated independent effects of HA and age. Patient-reported fatigue (p = 0.036), difficulty speaking (p = 0.049) and problems remembering things (p = 0.013) at 6 mos favored the HA-WBRT+M arm. Imputation models accounting for missing data also favored the HA-WBRT+M arm for patient-reported cognition (p = 0.011) and symptom interference (p = 0.008) at 6 mos. Treatment arms did not differ in toxicity, overall survival, or intracranial progression. Conclusions: HA during WBRT+M for BM better preserves NCF and patient-reported symptoms, while achieving similar intracranial control and survival. Supported by grants UG1CA189867 (NCORP), U10CA180868 (NRG Oncology Operations), DCP from the National Cancer Institute. Clinical trial information: NCT02360215.
Updated predictive analysis of the WHO-defined molecular subgroups of low-grade gliomas within the high-risk treatment arms of NRG Oncology/RTOG 9802.
Won, Minhee , McElroy, Joseph P., Shaw, Edward G. , Brachman, David, Gertler, Stanley Z., Murtha, Albert , Schultz, Christopher J. , Johnson, David , Hunter, G.K., Crocker, Ian , Chakravarti, Arnab , Bell, Erica H. , Fleming, Jessica L. , Becker, Aline Paixão , Mehta, Minesh P. , Laack, Nadia N.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: 2002-2002

10.1200/jco.2019.37.15_suppl.2002 Get It

2002 Background: This study sought to update the predictive significance of the three WHO-defined molecular glioma subgroups ( IDHwt, IDHmt/noncodel, and IDHmt/codel) in the subset of specimens available for analysis in NRG Oncology/RTOG 9802, a phase III trial of high-risk low-grade gliomas (LGGs) treated with radiation (RT) with and without PCV after biopsy/surgical resection. Notably, this is the first phase III study to evaluate the predictive value of the WHO subgroups in LGGs using prospectively-collected, well-annotated long-term overall survival data, in a post-hoc analysis. Methods: IDH1/2 mutation status was determined by immunohistochemistry and/or next-generation sequencing. 1p/19q status was determined by Oncoscan and/or 450K methylation data. Treatment effects on overall survival (OS) and progression-free survival (PFS) by marker status were determined by the Cox proportional hazard model and tested using the log-rank test in a secondary and exploratory analysis. Results: Of all the randomized eligible high-risk G2 patients (N = 251) in NRG Oncology/RTOG 9802, 106(42%) patients had tissue available with sufficient quality DNA for profiling. Of these, 80(75%) were IDHmut; 43(41%) were IDHmut/non-co-deleted, 37(35%) were IDHmut/co-deleted, and 26(24%) were IDHwt. Upon univariate analyses, no significant difference in either PFS or OS was observed with the addition of PCV in the IDHwt subgroup. Both the IDHmut/non-co-deleted and IDHmut/co-deleted subgroups were significantly correlated with longer PFS (HR = 0.32; p = 0.003; HR = 0.13; p < 0.001) and OS (HR = 0.38; p = 0.013; HR = 0.21; p = 0.029) in the RT plus PCV arm, respectively. Conclusions: Our analyses suggest that both IDHmut/non-co-deleted and IDHmut/co-deleted subgroups received benefit from treatment with PCV although sample size is limited and analyses are post-hoc. Our results also support the notion that IDHwt high-risk LGG patients do not benefit from the addition of PCV to RT. Funding: U10CA180868, U10CA180822, and U24CA196067. Also, R01CA108633, R01CA169368, RC2CA148190, U10CA180850-01, BTFC, OSU-CCC (all to AC). Clinical trial information: NCT00003375.
Tumor subtype and other prognostic factors in breast cancer patients with brain metastases: The updated graded prognostic assessment (Breast-GPA).
Sperduto, Paul W. , Cagney, Daniel , Nesbit, Eric , Chan, Jason W., Breen, Will, Soliman, Hany , Shanley, Ryan , Everett, Ashlyn S. , Masucci, Laura , Plichta, Kristin A. , Jain, Supriya , Bryant, John , Nakano, Toshimichi , Mesko, Shane , Lee, Jessica , Shi, Diana D. , Remick, Jill S. , Wu, Cheng–Chia , Yu, James B. , Mehta, Minesh P.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: 1079-1079

10.1200/jco.2019.37.15_suppl.1079 Get It

1079 Background: Brain metastases (BM) are a common and fatal complication of breast cancer but survival varies widely based on various prognostic factors (PF). Hence, patient counseling and therapeutic decisions should be individualized. We previously published a prognostic index (Breast GPA) based on cohort A (1985-2007, n = 642), updated it with tumor subtype in cohort B (1993-2010, n = 400) and are now updating it with a larger contemporary cohort (C). Methods: A multi-institutional (19) multi-national (3) retrospective database of 2473 breast cancer patients with BM diagnosed from 1/1/2006-12/31/2017 was created and compared to our prior cohorts. Demographic, clinical, molecular factors, tumor subtype and treatment were correlated with survival. Kaplan-Meier survival estimates were calculated and compared with log-rank tests. Results: The median survival (MS) for cohorts A, B and C improved over time [12, 14 and 16 mo, respectively ( < 0.01)] despite the subtype distribution becoming less favorable: Luminal B (ER/PR/HER2+) decreased from 26% to 21%; HER2 (HER2+/ER/PR-) decreased from 31% to 17%, Luminal A (ER/PR+/HER2-) increased from 20% to 31%; Basal (ER/PR/HER2-) was unchanged at 24%.MS by subtype improved from 21 to 27 mo in Luminal B, 18 to 25 mo in HER2, 10 to 14 mo in Luminal A and 6 to 9 mo in Basal tumors. The number of BM was 1 in 35%, ≤4 in 67% and > 10 in 18%. PF significant for survival were tumor subtype, age, KPS, number of BM and extracranial metastases (ECM) (all < 0.01). Surprisingly, Hispanic women (7%) showed improved survival (p < 0.01). BRCA1 was mutated in 57/533 (11%) and those patients showed a trend (0.16) toward improved survival. Treatment patterns have changed: the use of whole brain radiation therapy decreased from 71% to 67% to 47% in cohorts A, B and C, respectively. Conclusions: Despite the shift to less favorable tumor subtypes, MS has improvedbut varies widely by diagnosis-specific PF. Compared to prior cohorts, number of BM and ECM were identified as new PF. Ethnic, genetic and treatment differences between the eras are apparent. The updated Breast GPA, based on these data, and the correlation between BRCA1 and tumor subtype will be presented.
Clinical characteristics of a large cohort of US participants enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry, 2010–2015
Oskarsson, Björn , Mehta, Paul , Oskarsson, Björn , Raymond, Jaime S. , Horton, D. Kevin , Mehta, Paul

Mayo Clinic

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration | May 27, 2019 | Volume: 20 | Issue: 5-6 | Pages: 413-420

10.1080/21678421.2019.1612435 | PMID 31131638 Get It

Comparison of Endobronchial Ultrasound–guided Transbronchial Needle Aspiration With Stylet Retracted Partially Versus Completely for Molecular Testing
Fernández-Bussy, Sebastián , Biswas, Abhishek , Labarca, Gonzalo , Jantz, Michael A., Labarca, Gonzalo , Mehta, Hiren J.

Mayo Clinic

Journal of Bronchology & Interventional Pulmonology | May 17, 2019 | Volume: 26 | Issue: 3 | Pages: 222-224

10.1097/lbr.0000000000000596 | PMID 31107296 Get It

Background: Endobronchial ultrasound–guided transbronchial needle aspiration (EBUS-TBNA) is considered to be the initial diagnostic modality for most patients with lung cancer. However, the optimal technique for maximizing yield continues to vary in the real-world setting. Objectives: To evaluate the diagnostic yield of EBUS-TBNA with capillary sampling compared with complete stylet removal for molecular testing. Methods: Retrospective study, data from patients between January to May 2017 with indication of EBUS-TBNA whom ancillary testing, that is, next-generation sequencing, anaplastic lymphoma kinase ( ALK ), and programed death ligand-1 (PD-L1) expression was reviewed. The yield of 2 techniques, stylet retracted halfway (group 1) versus complete retraction (group 2), was compared. Results: A total of 24/27 (88.88%) samples were adequate for next-generation sequencing analysis in group 1 and 21/23 (91.30%) in group 2. For other molecular analyses, 24/27 (88.88%) samples in group 1 and 20/23 (86.95%) samples in group 2 were adequate for ALK analysis. 23/27 (85.18%) samples for group 1 and 20/23 (86.95%) samples for group 2 were adequate for PD-L1 analysis. Positive expression of PD-L1>50% was achieved in 9/23 (39.13%) of group 1 and 5/20 (25%) of group 2. There was no statistical difference in the yield between the 2 groups. Conclusion: EBUS-TBNA using either capillary sampling or complete stylet removal are effective and has a high proportion of satisfactory results for ancillary testing.
Quality Improvement Goals for Acute Kidney Injury
Kashani, Kianoush , Rosner, Mitchell H. , Lewington, Andrew , O’Donoghue, Dónal , Wilson, F. Perry , Nadim, Mitra K. , Silver, Samuel A. , Zarbock, Alexander , Ostermann, Marlies , Mehta, Ravindra L. , Kane‐Gill, Sandra L. , Pickkers, Peter , Bihorac, Azra , Siew, Edward D. , Frazee, Erin N. , Macedo, Etienne , Kellum, John A. , Tolwani, Ashita , Ronco, Claudio , Juncos, Luis A. , Rewa, Oleksa , Bagshaw, Sean M. , Mottes, Theresa , Liu, Kathleen D. , Heung, Michael , Wu, Vin‐Cent , Rewa, Oleksa G. , Wilson, F Perry , Mehta, Ravindra L , Ding, Xiaoqiang , Frazee, Erin N , Macedo, Etienne , Ronco, Claudio , Wu, Vin-Cent , Kane-Gill, Sandra L , Kashani, Kianoush B , Kellum, John A , Silver, Samuel A , Haase, Michael , Palevsky, Paul M. , Koyner, Jay L. , Forni, Lui G. , Bihorac, Azra , Bagshaw, Sean M , Juncos, Luis A , Ostermann, Marlies , Rewa, Oleksa G , Siew, Edward D

Mayo Clinic

Clinical Journal of the American Society of Nephrology | May 17, 2019 | Volume: 14 | Issue: 6 | Pages: 941-953

10.2215/cjn.01250119 | PMID 31101671 Get It

AKI is a global concern with a high incidence among patients across acute care settings. AKI is associated with significant clinical consequences and increased health care costs. Preventive measures, as well as rapid identification of AKI, have been shown to improve outcomes in small studies. Providing high-quality care for patients with AKI or those at risk of AKI occurs across a continuum that starts at the community level and continues in the emergency department, hospital setting, and after discharge from inpatient care. Improving the quality of care provided to these patients, plausibly mitigating the cost of care and improving short- and long-term outcomes, are goals that have not been universally achieved. Therefore, understanding how the management of AKI may be amenable to quality improvement programs is needed. Recognizing this gap in knowledge, the 22nd Acute Disease Quality Initiative meeting was convened to discuss the evidence, provide recommendations, and highlight future directions for AKI-related quality measures and care processes. Using a modified Delphi process, an international group of experts including physicians, a nurse practitioner, and pharmacists provided a framework for current and future quality improvement projects in the area of AKI. Where possible, best practices in the prevention, identification, and care of the patient with AKI were identified and highlighted. This article provides a summary of the key messages and recommendations of the group, with an aim to equip and encourage health care providers to establish quality care delivery for patients with AKI and to measure key quality indicators.